Gloudemans, Michael J.
Balliu, Brunilda
Nachun, Daniel
Schnurr, Theresia M.
Durrant, Matthew G.
Ingelsson, Erik
Wabitsch, Martin
Quertermous, Thomas
Montgomery, Stephen B.
Knowles, Joshua W.
Carcamo-Orive, Ivan
Funding for this research was provided by:
national institute of diabetes and digestive and kidney diseases (R01 DK120565, R01 DK116750, R01 DK106236, R01 DK107437, P30DK116074)
u.s. national library of medicine (T15 LM 007033)
national institute on aging (1T32AG047126-01, R01 AG066490)
american diabetes association (1-19-JDF-108)
national institute of mental health (R01 MH125244)
national human genome research institute (U01 HG009431)
national heart, lung, and blood institute (R01 HL142015)
Article History
Received: 19 August 2021
Accepted: 4 March 2022
First Online: 15 March 2022
Declarations
:
: Not applicable.
: Not applicable.
: SBM is a consultant for BioMarin, Myome, and Tenaya Therapeutics. EI is currently an employee at GlaxoSmithKline, but this work was done while he was still employed at Stanford University. The remaining authors declare that they have no competing interests.